The rapid rise of glucagon-like peptide-1 (GLP-1) receptor agonists has transformed the landscape of obesity management, offering unprecedented weight loss results for millions of individuals worldwide. However, a new analysis of real-world data suggests a concerning trend: as patients lose weight on these medications, their physical activity levels appear to decrease rather than increase. This finding challenges the long-held assumption that weight loss naturally serves as a catalyst for a more active lifestyle. According to a study presented at the Endocrine Society’s annual meeting, ENDO 2024, by lead researcher Sajana Maharjan, MD, of HSHS St. John’s Hospital in Springfield, Illinois, patients utilizing these medications saw a measurable decline in both daily step counts and minutes of moderate-to-vigorous physical activity.
The retrospective study utilized data from the National Institutes of Health’s (NIH) "All of Us" Research Program, a massive longitudinal effort designed to build a diverse health database. By linking participants’ electronic health records (EHR) with objective data from wearable fitness trackers, specifically Fitbit devices, researchers were able to gain a rare, unfiltered look at how GLP-1 medications—including semaglutide, liraglutide, dulaglutide, and tirzepatide—impacted the daily movement patterns of patients in a real-world setting.
The Core Findings: A Decline in Daily Movement
The study focused on a cohort of 1,950 adults diagnosed with obesity who were prescribed GLP-1 receptor agonists. From this group, researchers identified 753 individuals who provided sufficient wearable device data to allow for a robust pre-and-post-medication analysis. The demographics of the cohort were predominantly female (78.6%), with a mean age of 52.7 years, representing a significant portion of the population currently seeking pharmacological interventions for weight management.
The results revealed a statistically significant reduction in physical activity following the initiation of GLP-1 therapy. Before starting the medication, the average daily step count for participants was 5,047 steps. After beginning the treatment, this figure dropped to 4,487 steps per day—a decrease of approximately 560 steps. Perhaps more concerning was the decline in moderate-to-vigorous physical activity (MVPA), which is the type of exercise most closely associated with cardiovascular health and metabolic maintenance. MVPA minutes fell from an average of 28 minutes per day to just 22 minutes.
Dr. Maharjan noted that while many clinicians and patients expect that shedding excess weight will reduce the physical burden of movement and thus lead to increased activity, the data suggests the opposite. This "activity paradox" suggests that weight loss achieved through GLP-1 agonists does not automatically translate into the adoption of a more active lifestyle, and in many cases, it may actually lead to a more sedentary routine.
Understanding the Physiological Risks of Muscle Loss
One of the primary concerns raised by Dr. Maharjan and her team involves the composition of the weight being lost. GLP-1 receptor agonists are highly effective at reducing total body mass, but that mass loss is not exclusively fat. Clinical trials have consistently shown that a significant portion of the weight lost on these medications—often ranging from 20% to 40%—comes from lean muscle mass.
Muscle tissue is metabolically active and essential for maintaining strength, balance, and long-term metabolic health. When patients lose muscle mass without engaging in resistance training or consistent physical activity, they risk developing "sarcopenic obesity," a condition where an individual has high body fat but low muscle mass. This can lead to increased frailty, a lower resting metabolic rate, and a higher likelihood of weight regain once the medication is discontinued.
"The findings in our study reinforce that exercise cannot be optional for people taking these medications," Dr. Maharjan emphasized during her presentation. "Because these drugs reduce not only fat but also lean muscle mass, physical activity is essential for preserving strength and long-term health."
Factors Influencing the Decline in Activity
The study delved deeper into the data to identify which subgroups were most affected by this decline in movement. The researchers found that the largest drops in physical activity occurred among men and individuals who reported pre-existing joint or muscle pain. This suggests that for some, the side effects of the medication or the physiological changes of rapid weight loss might exacerbate existing physical limitations or create new barriers to exercise.
Interestingly, the study found that certain comorbidities did not significantly alter the trend. Factors such as age, a history of heart failure, or a prior stroke did not change the overall result; the decline in activity remained consistent across these groups. This indicates that the trend is a broad phenomenon associated with the medication use itself rather than being confined to specific high-risk health demographics.
While the study did not explicitly track the causes of the decline, medical experts have pointed to several potential factors. GLP-1 medications are known to cause gastrointestinal side effects, including nausea, vomiting, and fatigue, particularly during the dose-escalation phase. These side effects can significantly dampen a patient’s motivation or physical ability to engage in exercise. Furthermore, the rapid reduction in caloric intake associated with these drugs can sometimes lead to a "low energy" state, where patients feel less inclined to participate in vigorous movement.
The Role of the "All of Us" Research Program
The use of the NIH "All of Us" Research Program data marks a significant milestone in obesity research. This is the first large-scale study to utilize objective data from wearable fitness trackers to analyze the behavior of adults taking GLP-1 receptor agonists. Unlike self-reported surveys, which are often prone to "social desirability bias"—where patients overstate their exercise habits—Fitbit data provides an objective, minute-by-minute account of a patient’s actual movement.
The "All of Us" program aims to collect data from one million or more people living in the United States to accelerate health research and medical breakthroughs. By linking genetic, environmental, and lifestyle data with EHRs, the program allows researchers to see how medications perform in the "real world" as opposed to the highly controlled environments of clinical trials. The insights gained from this study highlight the value of digital health tools in monitoring patient progress and identifying unintended consequences of even the most successful treatments.
Clinical Implications and Targeted Interventions
The implications of Dr. Maharjan’s research are far-reaching for the clinical community. As the prescription volume for GLP-1s continues to soar, healthcare providers are being urged to move beyond simply monitoring the number on the scale. The study suggests that a "medication-only" approach to obesity may be insufficient for long-term health.
Medical professionals are now calling for "targeted interventions" that integrate physical activity counseling and structured exercise programs into the standard of care for patients on GLP-1 therapy. This could include:
- Prescriptive Exercise: Treating exercise as a vital component of the prescription, with specific recommendations for resistance training to counteract muscle loss.
- Continuous Monitoring: Using wearable technology to track patient activity in real-time, allowing clinicians to intervene if they see a significant drop in step counts.
- Nutritional Support: Ensuring patients consume adequate protein to support muscle maintenance while in a caloric deficit.
- Behavioral Coaching: Addressing the psychological and physiological barriers to movement that may arise during treatment.
Dr. Maharjan argued that the assumption that weight loss leads to activity must be replaced with a proactive strategy. "People need targeted interventions that encourage physical activity alongside medication for obesity," she stated.
The Broader Context of GLP-1 Medications
The medications included in the study represent the current "gold standard" in weight management. Semaglutide (marketed as Wegovy for weight loss and Ozempic for diabetes) and tirzepatide (marketed as Zepbound for weight loss and Mounjaro for diabetes) have shown weight loss results of 15% to 22% of total body weight in clinical trials.
However, as these drugs move from clinical trials to the general population, researchers are increasingly looking at the "quality" of weight loss. The medical community is shifting its focus from "weight loss" to "metabolic health." If a patient loses 50 pounds but also loses the strength to climb stairs or maintain a healthy cardiovascular system, the net benefit to their longevity may be compromised.
The timeline of GLP-1 development shows a rapid acceleration in adoption. Liraglutide (Saxenda) was approved for weight management in 2014, but it was the 2021 approval of Wegovy that sparked the current surge. Since then, the conversation has moved from glycemic control to total body transformation. This latest study adds a necessary layer of caution to the narrative, reminding the public and providers alike that pharmacological success does not replace the fundamental pillars of health: diet and exercise.
Future Research and Unanswered Questions
While the study provides a clear snapshot of declining activity, it also opens the door for further investigation. Future research is needed to determine if activity levels eventually rebound after a patient has been on a stable dose for an extended period. Additionally, more data is needed on whether specific types of GLP-1 agonists have different effects on activity levels—for example, whether the dual-action mechanism of tirzepatide (which targets both GLP-1 and GIP receptors) results in different energy levels compared to semaglutide.
There is also the question of the "why" behind the gender disparity observed in the data. With men showing larger declines in activity than women, researchers may need to investigate whether there are biological or lifestyle-based reasons for this difference.
Conclusion
The findings presented at ENDO 2024 serve as a vital wake-up call for the millions of people utilizing GLP-1 medications and the doctors who prescribe them. While the ability of these drugs to reduce weight is undeniable, the reduction in daily steps and moderate-to-vigorous physical activity suggests that the "easy path" to weight loss may have hidden costs.
To ensure that the weight loss achieved through these breakthrough medications leads to a healthier, longer life, the medical community must emphasize that exercise is a non-negotiable partner to pharmacology. As Dr. Maharjan’s analysis clearly demonstrates, losing the weight is only half the battle; maintaining the movement is what will ultimately define the success of the modern obesity treatment revolution. In the absence of proactive movement, the benefits of a thinner frame may be undermined by the loss of the very muscle and stamina required to enjoy a more active, healthier life.
